Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUE-101 and Pembrolizumab in Newly Diagnosed, Locally Advanced HPV-16+ Head and Neck Cancer
NCT07172256Phase 2Recruiting
- Sponsor
- Yale University
- Start
- May 2026
- Primary completion
- Feb 2031
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of CUE-101 in head and neck squamous cell carcinoma (HNSCC), sponsored by Yale University. Started May 2026; status: recruiting.
02
Drugs
CUE-101
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07172256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172256.